Gilead boosts cancer and inflammation portfolio with XinThera buy

Announcing its first M&A deal in more than a year, California, USA-based Gilead Sciences (Nasdaq: GILD) said yesterday that it has acquired privately-held US biotech XinThera.

The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation.

Through the acquisition, Gilead gains rights to a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases that could enter clinical trials later this year. Both programs have the potential to address multiple indications, offering broad development opportunities alone and in combination with Gilead’s portfolio.